CLIA Waiver for IVDs: Submission Strategy, Study Design, and Dual 510(k) Pathway
Plan a CLIA waiver strategy for IVDs, covering complexity categories, CW content, flex and lay-user studies, Dual 510(k) + CLIA Waiver review, timelines, and deficiencies.
Why CLIA Waiver Matters for IVD Market Access
Obtaining a CLIA waiver determination dramatically expands the market for an IVD product. A CLIA-waived test can be performed in approximately 225,000 laboratory sites operating under a Certificate of Waiver — pharmacies, physician office laboratories, urgent care clinics, community health centers, and other near-patient settings. Without waiver, a test categorized as moderate or high complexity can only be performed in laboratories with appropriate certification, severely limiting commercial reach.
Under the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. § 263a), FDA shares CLIA oversight responsibilities with CMS and CDC. FDA is responsible for categorizing test complexity and reviewing waiver applications. The statutory criteria for waiver are clear: the test must employ methodologies that are so simple and accurate as to render the likelihood of erroneous results by the user negligible, or pose no unreasonable risk of harm if performed incorrectly.
This guide provides a complete playbook for obtaining CLIA waiver, from initial strategy through submission and review.
CLIA Complexity Categories
Category Overview
| Category | Certificate Required | Typical Test Settings | Personnel Requirements | QC Requirements |
|---|---|---|---|---|
| Waived | Certificate of Waiver | Physician offices, pharmacies, urgent care, home use | Minimal training; follow manufacturer instructions | Follow manufacturer instructions |
| Moderate Complexity | Certificate of Compliance or Accreditation | Hospital labs, reference labs, POLs with certification | Testing personnel with associate degree or equivalent | Standard QC, proficiency testing |
| High Complexity | Certificate of Compliance or Accreditation | Reference labs, specialized testing facilities | BS in science + appropriate training; director with doctoral degree | Full QC, proficiency testing, method validation |
Waived Test Criteria (42 U.S.C. § 263a(d)(3))
A test qualifies for waiver if it meets any of these criteria:
FDA-approved for home use — automatically waived
Simple methodology with negligible error risk — employs methodologies so simple and accurate that erroneous results are unlikely
No unreasonable risk of harm — even if performed incorrectly, the test poses no unreasonable risk to the patient
Pathways to Waiver
| Pathway | When to Use | Key Characteristic |
|---|---|---|
| Automatic waiver | Test is cleared/approved for home/OTC use | No separate waiver application needed |
| CLIA Waiver by Application (CW) | Test is already cleared/approved (510(k), PMA, De Novo) | Standalone waiver application after authorization |
| Dual 510(k) + CLIA Waiver | New test seeking both clearance and waiver simultaneously | Single submission with combined evidence package |
The Dual 510(k) + CLIA Waiver Pathway
Overview
The Dual 510(k) and CLIA Waiver by Application pathway was established under MDUFA III (Medical Device User Fee Amendments of 2012). It allows manufacturers to submit a single package containing both a complete 510(k) and a CLIA Waiver by Application. FDA considers this the least burdensome and fastest approach for obtaining both clearances.
Dual Submission Process
| Step | Action | Timeline |
|---|---|---|
| 1 | Submit a Pre-Submission informing FDA of Dual Submission plans | 60–90 days before submission |
| 2 | Discuss proposed study designs in Pre-Sub meeting | During Pre-Sub review |
| 3 | Submit Dual package (510(k) + CW) with cover letter referencing Pre-Sub number | Day 0 |
| 4 | eCopy requirements apply; 510(k) MDUFA User Fee required | At submission |
| 5 | RTA (Refuse to Accept) screening applies to complete package | First 15 calendar days |
| 6 | Substantive Interaction | By 90 FDA Days |
| 7 | MDUFA Decision | By 180 FDA Days |
Review Timelines
| Submission Type | Substantive Interaction | MDUFA Decision |
|---|---|---|
| CLIA Waiver by Application (standalone) | 90 FDA Days | 150 FDA Days (no panel) / 320 (with panel) |
| Dual 510(k) + CLIA Waiver | 90 FDA Days | 180 FDA Days |
| 510(k) only | 60 FDA Days | 90 FDA Days |
User Fees
| Submission Type | MDUFA User Fee (FY 2026) |
|---|---|
| 510(k) | $26,067 (FY2026 standard) |
| CLIA Waiver by Application (standalone) | No user fee |
| Dual 510(k) + CLIA Waiver | 510(k) fee only (no additional CLIA fee) |
CW Submission Content Requirements
A CLIA Waiver by Application must include the following:
Required Elements
| Element | Description | Key Content |
|---|---|---|
| Cover letter | Signed, dated; identifies submission as CW or Dual; references cleared/approved application (for standalone CW) | Contact information, 510(k)/PMA reference number |
| Device description | Demonstrates simplicity of use | Intuitive workflow, minimal steps, automated processes |
| Risk analysis | Identification of potential error sources | FMEA, fault tree analysis, hazard analysis |
| Risk mitigation | Measures to control identified errors | Fail-safe mechanisms, error alerts, built-in controls |
| Flex studies | Demonstrate insensitivity to environmental and usage variations | Temperature, humidity, specimen handling, operator errors |
| Accuracy study | Demonstrate comparable performance between waived and trained users | Lay-user testing vs. moderate-complexity laboratory users |
Flex Study Design
Flex studies test the device's robustness to variations in use conditions that might occur in waived settings:
| Flex Parameter | Test Approach | Typical Conditions Tested |
|---|---|---|
| Temperature | Test at extremes of claimed storage and operating range | 15–30°C operating; refrigerated and room temp storage |
| Humidity | Test at high and low humidity extremes | 20–80% relative humidity |
| Specimen handling | Test with common user errors in specimen collection and application | Incorrect volume, delayed application, reapplication |
| Timing errors | Test with early and late read times | ±25–50% of recommended read time |
| Operator variability | Test with untrained operators (lay users) | Operators with no laboratory training |
| Reagent handling | Test with common reagent mishandling scenarios | Reagent expiration, improper storage, reuse |
| Interfering substances | Test in presence of common interferents | Per CLSI EP07 / EP37 |
Lay-User (Operator) Study Design
The lay-user study is the cornerstone of the CW application. It demonstrates that untrained operators can achieve results comparable to trained laboratory professionals.
| Parameter | Recommendation |
|---|---|
| Operator selection | Minimum 20 untrained operators at ≥3 sites; no laboratory science background |
| Site selection | ≥3 sites representative of waived settings (physician offices, urgent care, pharmacies) |
| Specimen type | Fresh clinical specimens recommended; contrived specimens may supplement |
| Comparison | Operator results compared to trained laboratory professionals using same device |
| Statistical approach | Comparable performance between lay users and trained users; predefined acceptance criteria |
| Error handling | Document all operator errors, device errors, and invalid results |
| Training | Operators receive only the instructions for use — no additional training beyond what would accompany the product |
Accuracy Standards
FDA's revised guidance (February 2020) accepts "comparable performance" between waived users and moderately complex laboratory users as evidence of accuracy. This means:
| Metric | Acceptance Criterion |
|---|---|
| Positive percent agreement (PPA) | Comparable to trained user performance, typically ≥95% |
| Negative percent agreement (NPA) | Comparable to trained user performance, typically ≥95% |
| Invalid rate | Low; typically <5% of total tests |
| Error recovery | Device must provide clear error messages or fail-safe mechanisms |
Sequential vs. Dual Submission
| Factor | Sequential (510(k) first, then CW) | Dual (510(k) + CW together) |
|---|---|---|
| Total timeline | 90 days (510(k)) + 150 days (CW) = ~240 days total | 180 days total |
| User fees | 510(k) fee + no CW fee | 510(k) fee only |
| Risk | Lower — can address 510(k) questions before CW | Higher — CW issues may delay 510(k) decision |
| Data generation | May leverage 510(k) clinical data for CW | Studies planned to serve both purposes |
| FDA engagement | Two separate review cycles | One integrated review |
| Best for | Devices where waiver is uncertain or secondary | Devices designed from the start for waived settings |
Common Deficiencies in CLIA Waiver Applications
Top 10 Reasons for Additional Information Requests
| Rank | Deficiency | Description |
|---|---|---|
| 1 | Inadequate flex study design | Insufficient conditions tested, not representative of waived settings |
| 2 | Insufficient operator diversity | Too few operators, operators too experienced, single site |
| 3 | Missing risk analysis | No systematic identification of potential error sources |
| 4 | Inadequate sample size | Too few specimens for statistical significance |
| 5 | Non-representative specimen types | Only contrived specimens; no fresh clinical specimens |
| 6 | Undefined acceptance criteria | No pre-specified success criteria for accuracy |
| 7 | Training bias | Operators received more training than IFU provides |
| 8 | Inadequate device simplicity documentation | Device has complex steps not suitable for lay users |
| 9 | Missing fail-safe mechanism validation | Error detection features not validated under flex conditions |
| 10 | Poor comparison methodology | Reference method inappropriate or not adequately described |
Real-World Example: LEX Diagnostics VELO System
In June 2025, LEX Diagnostics submitted dual applications for FDA 510(k) clearance and CLIA waiver for its VELO system — an ultrafast point-of-care molecular diagnostics platform. The system delivers PCR results for respiratory pathogens (Influenza A, Influenza B, COVID-19) in under 10 minutes from a swab sample. Key features that support the Dual pathway:
Cartridge-based design eliminates external liquid handling
Simple workflow designed for non-laboratory personnel
Multiplex testing for key respiratory pathogens
Clinical studies completed in the US during 2024–2025 respiratory season
On February 13, 2026, FDA granted both 510(k) clearance (K251742) and CLIA waived status for the VELO Respiratory Test — demonstrating the Dual pathway timeline of approximately 8 months from submission to decision. LEX completed US clinical studies during the 2024–2025 respiratory season and was acquired by QuidelOrtho Corporation in 2026.
EUA-to-Dual Pathway Transition
For IVDs authorized under Emergency Use Authorization (EUA) for use in CLIA-waived settings, Section 3301 of the Food and Drug Omnibus Reform Act of 2022 (FDORA) allows transition through the Dual 510(k) + CLIA Waiver pathway, or Dual De Novo + CLIA Waiver for novel devices. Key considerations:
EUA tests used in waived settings should transition to traditional marketing authorization
The Dual pathway is the recommended route for EUA-to-market transition
Pre-Submission discussion with FDA is especially important for EUA transitions
Submission Readiness Checklist
Pre-Submission Phase
Determine whether the device is designed for waived settings from the start
Assess whether the device meets the statutory simplicity criteria
Conduct preliminary risk analysis identifying potential user errors
Submit Pre-Submission to FDA describing Dual Submission plans
Discuss proposed flex study and lay-user study designs with FDA
Study Execution Phase
Complete flex studies covering temperature, humidity, timing, specimen handling
Conduct lay-user study at ≥3 representative waived settings
Enroll ≥20 untrained operators with no laboratory background
Use fresh clinical specimens supplemented by contrived panels
Pre-define acceptance criteria for accuracy, invalid rate, and error detection
Document all operator errors, device errors, and corrective actions
Validate fail-safe mechanisms under flex conditions
Submission Phase
Cover letter identifying submission as Dual (510(k) + CW)
Reference Pre-Submission number in cover letter
Complete 510(k) eSTAR template
Include device description demonstrating simplicity
Include risk analysis with error source identification
Include risk mitigation measures and validation data
Include flex study reports
Include lay-user accuracy study reports
Pay 510(k) MDUFA User Fee
Submit via electronic submission (eCopy)
Post-Submission Phase
Respond to RTA screening questions within 15 calendar days
Prepare for Substantive Interaction by Day 90
Address Additional Information requests promptly
Prepare for potential panel meeting (if applicable)
Key Takeaways
The Dual pathway is the fastest route. At 180 days total, it is significantly faster than the sequential approach (~240 days), with no additional user fee.
Pre-Submissions are essential. FDA expects manufacturers to discuss Dual Submission plans and study designs through the Pre-Submission process before filing.
Lay-user study design is critical. FDA scrutinizes operator selection, site selection, and training to ensure the study truly represents waived-setting conditions.
Flex studies demonstrate robustness. The device must be insensitive to environmental and usage variations likely encountered in non-laboratory settings.
Comparable performance is the standard. The revised 2020 guidance accepts comparable performance between lay users and trained laboratory professionals as evidence of accuracy.
Common deficiencies are preventable. Most additional information requests stem from inadequate study design, insufficient operators, or missing risk analysis — all addressable through proper planning.
EUA-to-market transitions should use the Dual pathway. Section 3301 of FDORA provides a clear route for EUA tests that were used in waived settings.
Sources
FDA. "CLIA Waiver by Application." Updated 2025.
FDA. "Recommendations for Dual 510(k) and CLIA Waiver by Application Studies." Guidance for Industry and FDA Staff.
FDA. "Recommendations for CLIA Waiver Applications for Manufacturers of IVD Devices." February 2020.
42 U.S.C. § 263a(d)(3) — Clinical Laboratory Improvement Amendments.
NIH SEED. "CLIA Waived Tests." December 2024.
CMS. "QSO-25-10-CLIA: Certificate of Waiver Requirements." Revised June 2025.
Baker Donelson. "CMS Enacts New CLIA Regulations Effective January 2025."
Westgard QC. "2025 CLIA Acceptance Limits for Proficiency Testing."
LEX Diagnostics Press Release. "LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver." June 2025.
LEX Diagnostics Press Release. "LEX Diagnostics Receives FDA 510(k) Clearance and CLIA Waiver for LEX VELO System." February 2026.
FDA. "Administrative Procedures for CLIA Categorization." Guidance Document.
Federal Register. "CLIA Categorization and Waiver Information Collection." November 2025 (90 FR).